These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28461327)

  • 1. Minimization of olaratumab drug waste using real-world data.
    Sheffield KM; Beyrer JK; Watson IA; Stafford K; Mills BJ; Ale-Ali A
    Am J Health Syst Pharm; 2017 Jun; 74(11):832-842. PubMed ID: 28461327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil.
    Clark L; Castro AP; Fortes AF; Santos F; Clark O; Engel T; Pegoretti B; Teich V; Vianna D; Puty F
    Value Health; 2011; 14(5 Suppl 1):S82-4. PubMed ID: 21839906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
    Andrick BJ; Gandhi A
    Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages.
    Del Río-Valencia JC; Asensi-Díez R; Villalobos-Torres L; Clopés-Estela A; Fraga-Fuentes MªD
    Farm Hosp; 2018 Sep; 42(5):204-211. PubMed ID: 30173639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
    Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
    Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding.
    Lindsey S; Parsons LB; Figg LR; Rhodes J
    J Oncol Pharm Pract; 2018 Jan; 24(1):47-55. PubMed ID: 29251257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
    Antoniou G; Lee ATJ; Huang PH; Jones RL
    Eur J Cancer; 2018 Mar; 92():33-39. PubMed ID: 29413687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.
    Copur MS; Gnewuch C; Schriner M; Tharnish M; Gonen M; McDonald M; Kezeor J; Ramaekers RC; Gauchan D; Clark D; Greenwalt L; Mickey M; Norvell M
    J Oncol Pharm Pract; 2018 Mar; 24(2):116-120. PubMed ID: 29284380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the potential impact of dose rounding parenteral chemotherapy agents on cost savings and drug waste minimization.
    Chillari KA; Southward J; Harrigan N
    J Oncol Pharm Pract; 2018 Oct; 24(7):507-510. PubMed ID: 28732452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential cost savings associated with dose rounding antineoplastic monoclonal agents.
    Francis SM; Heyliger A; Miyares MA; Viera M
    J Oncol Pharm Pract; 2015 Aug; 21(4):280-4. PubMed ID: 24821690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.
    Hess LM; Cui ZL; Li XI; Oton AB; Shortenhaus S; Watson IA
    J Med Econ; 2018 Aug; 21(8):755-761. PubMed ID: 29673274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of dose rounding of chemotherapy to the nearest vial size.
    Dooley MJ; Singh S; Michael M
    Support Care Cancer; 2004 Sep; 12(9):653-6. PubMed ID: 14986078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world data approach to determine the optimal dosing strategy for pembrolizumab.
    Jang A; Nakashima L; Ng T; Fung M; Jiwani S; Schaff K; Suess J; Goncalves R; Jang D; Kuik K; Labelle S; Pow A
    J Oncol Pharm Pract; 2021 Apr; 27(3):635-643. PubMed ID: 32539663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.
    Seeber A; Weiss L; Romeder F; Szkandera J; Kuehr T; Kostner S; Pichler P; Jaeger T; Kocher F; Greil R; Brodowicz T
    Wien Klin Wochenschr; 2021 Jan; 133(1-2):21-25. PubMed ID: 31620878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaratumab for the treatment of advanced soft tissue sarcoma.
    Okuno SH; Maran A; Robinson SI
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):883-887. PubMed ID: 28862476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaratumab for advanced soft tissue sarcoma.
    Tobias A; O'brien MP; Agulnik M
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):699-705. PubMed ID: 28447475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
    Davis EJ; Chugh R
    Drug Des Devel Ther; 2017; 11():3579-3587. PubMed ID: 29263653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaratumab for the treatment of soft-tissue sarcoma.
    Pender A; Jones RL
    Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaratumab in the management of advanced soft tissue sarcoma.
    Zobniw CM; Trinh VA; Posey K; Somaiah N
    J Oncol Pharm Pract; 2019 Mar; 25(2):442-448. PubMed ID: 30032714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.